Results 181 to 190 of about 1,512,475 (325)

Nonavalent HPV vaccine to prevent recurrent anal or vulvar high‐grade squamous intraepithelial lesions (VIVA trial): A randomized, double‐blind, placebo‐controlled trial

open access: yesInternational Journal of Cancer, Volume 158, Issue 11, Page 2983-2994, 1 June 2026.
What's new? Anal and vulvar high‐grade squamous intraepithelial lesions (HSILs) frequently recur following treatment. Additional genital and anal procedures, however, can be distressing for patients and are potentially disfiguring. This trial assessed whether the 9‐valent human papillomavirus (9vHPV) vaccine reduces HSIL recurrence risk or HPV ...
Helen C. Stankiewicz Karita   +13 more
wiley   +1 more source

Oral Microbiome Resilience During SARS‐CoV‐2 Infection and Diversity Shifts After COVID‐19 Vaccination in a Hispanic Population

open access: yesMicrobiologyOpen, Volume 15, Issue 3, June 2026.
The oral microbiome in Hispanics remains largely resilient during mild SARS‐CoV‐2 infection, showing minimal diversity changes, while COVID‐19 vaccination induces increased microbial evenness and compositional shifts. These findings highlight limited infection impact but suggest vaccination transiently reshapes oral microbial ecology.
Daniela Vargas‐Robles   +8 more
wiley   +1 more source

Cost‐Effectiveness Analysis of Second‐Line Lisocabtagene Maraleucel in the Treatment of Refractory or Relapsed Large B‐Cell Lymphoma

open access: yesEuropean Journal of Haematology, Volume 116, Issue 6, Page 797-805, June 2026.
ABSTRACT Objectives CAR‐T cell therapies such as lisocabtagene maraleucel (liso‐cel) have transformed the treatment of patients with second line primary refractory or early relapsed ≤ 12 months (R/R) large B‐cell lymphoma (LBCL). The objective of this study was to assess the cost‐effectiveness of liso‐cel compared to standard of care (SOC) to treat R/R
Catherine Thieblemont   +6 more
wiley   +1 more source

Biotecnología moderna y su estudio en la carrera de Derecho [PDF]

open access: yes, 2016
Artículo de ReflexiónCon este artículo se pretende dar a conocer los conceptos básicos de lo que es Biotecnología moderna y también, fijar un referente de reflexión que permita puntualizar en la necesidad de implementar una nueva materia curricular en ...
Rubiano-Sandoval, Lina María
core  

Contextualizing the Cappella Cesi: Sangallo, Façades, and Renaissance Collaboration

open access: yesRenaissance Studies, Volume 40, Issue 3, Page 489-506, June 2026.
Abstract This article reframes Antonio da Sangallo the Younger's oft‐overlooked cappella Cesi nave façade in Santa Maria della Pace not as an isolated design deviation but as part of a broader architectural and artistic conversation among major players in early sixteenth‐century Rome.
Alexis Culotta
wiley   +1 more source

A dança moderna

open access: yes, 2016
O livro A dança moderna foi originalmente publicado em 1933 pela Princeton Book Company, reunindo, numa só obra, quatro conferências sobre a dança, analisada sob uma perspectiva filosófica, proferidas por John Martin na New School for Social Research em New York em 1931 e 1932.
openaire   +3 more sources

Intervenciones en la arquitectura moderna [PDF]

open access: yes, 2013
Las teorías de la arquitectura moderna, sustentadas en ideas de eficiencia técnica, objetividad funcional y representación estética, fueron el sustento de una producción edilicia caracterizada por estructuras tridimensionales de racionalidad numérica que
Tarchini, María Laura
core  

Lipid Nanoparticles for the Delivery of CRISPR/Cas9 Machinery to Enable Site‐Specific Integration of CFTR and Mutation‐Agnostic Disease Rescue

open access: yesAdvanced Functional Materials, Volume 36, Issue 36, 4 May 2026.
Lipid nanoparticles (LNPs) are optimized to co‐deliver Cas9‐encoding messenger RNA (mRNA), a single guide RNA (sgRNA) targeting the endogenous cystic fibrosis transmembrane conductance regulator (CFTR) gene, and homologous linear double‐stranded donor DNA (ldsDNA) templates encoding CFTR.
Ruth A. Foley   +12 more
wiley   +1 more source

Fianlimab, a human lymphocyte activation gene‐3 monoclonal antibody, in combination with cemiplimab: Tumor‐specific expansion cohorts in advanced malignancies

open access: yesCancer, Volume 132, Issue 9, 1 May 2026.
Abstract Background The dose escalation phase of a first‐in‐human (FIH) study demonstrated acceptable safety and preliminary antitumor activity of fianlimab (anti‐lymphocyte activation gene‐3 [LAG‐3]) as monotherapy and in combination with cemiplimab (anti‐programmed cell death‐1 [PD‐1]). Here, the authors present safety and clinical activity data from
Tae Min Kim   +25 more
wiley   +1 more source

De novo vasculitis after mRNA-1273 (Moderna) vaccination

open access: yesKidney International, 2021
M. Anderegg   +6 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy